These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 2897925)

  • 41. The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions.
    Zivin M; Sprah L; Sket D
    Br J Pharmacol; 1996 Nov; 119(6):1187-96. PubMed ID: 8937722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Further dopaminergic supersensitivity to dopamine agonists by subchronic administration of haloperidol in rats treated with colchicine.
    Kamata K; Okuyama S; Hashimoto S; Aihara H; Kasuya Y
    Jpn J Pharmacol; 1986 Oct; 42(2):329-32. PubMed ID: 3795627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of SCH 39166, a novel dopamine D1 receptor antagonist, on [3H]acetylcholine release in rat striatal slices.
    Tedford CE; Crosby G; Iorio LC; Chipkin RE
    Eur J Pharmacol; 1992 Feb; 211(2):169-76. PubMed ID: 1535318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.
    Erzin-Waters C; Muller P; Seeman P
    Can J Physiol Pharmacol; 1976 Aug; 54(4):516-9. PubMed ID: 10058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK&F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide.
    Molloy AG; Waddington JL
    Eur J Pharmacol; 1985 Feb; 108(3):305-8. PubMed ID: 3886407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Haloperidol, but not apomorphine, differentially affects low response rates of male and female Wistar rats.
    Van Hest A; van Haaren F; van de Poll NE
    Pharmacol Biochem Behav; 1988 Mar; 29(3):529-32. PubMed ID: 3362947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brexpiprazole has a low risk of dopamine D
    Amada N; Akazawa H; Ohgi Y; Maeda K; Sugino H; Kurahashi N; Kikuchi T; Futamura T
    Neuropsychopharmacol Rep; 2019 Dec; 39(4):279-288. PubMed ID: 31487433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Altered response to apomorphine and haloperidol after nine days of cocaine injections.
    Epstein PN; Altshuler HL
    Pharmacol Biochem Behav; 1979 Feb; 10(2):189-93. PubMed ID: 572056
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug-induced rotation in rats without lesions: behavioral and neurochemical indices of a normal asymmetry in nigro-striatal function.
    Jerussi TP; Glick SD
    Psychopharmacology (Berl); 1976 Jun; 47(3):249-60. PubMed ID: 823560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
    Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
    Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models.
    Gerhardt S; Gerber R; Liebman JM
    Life Sci; 1985 Dec; 37(25):2355-63. PubMed ID: 3908866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
    Gulati A; Srimal RC; Dhawan BN
    Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electrophysiological and behavioral assessments of dopamine autoreceptor activation to apomorphine in rats.
    Okuyama S; Shimamura H; Hashimoto S; Aihara H
    Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):246-54. PubMed ID: 3827410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166.
    Prinssen EP; Ellenbroek BA; Stamatovic B; Cools AR
    Eur J Pharmacol; 1993 Feb; 231(2):275-80. PubMed ID: 8095900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    Breese GR; Napier TC; Mueller RA
    J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of thioridazine on haloperidol induced behavioral hypersensitivity.
    Klawans HL; Carvey PM; Nelson D; Tanner CM; Goetz CG
    Life Sci; 1986 May; 38(19):1707-14. PubMed ID: 3702600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apomorphine-induced stereotypy in mature and senescent rats following cessation of chronic haloperidol treatment.
    Roffman M; Cordasco F; Kling A
    Commun Psychopharmacol; 1980; 4(4):283-6. PubMed ID: 7196824
    [No Abstract]   [Full Text] [Related]  

  • 60. Behavioral pharmacologic studies in the monkey with DD-3480.
    Shibuya T; Nishimori T; Matsuda H; Chen PC
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):251-4. PubMed ID: 6125481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.